Capricor Therapeutics Inc(CAPR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAPR Capricor Therapeutics Inc

休市中 09-04 16:00:00 EDT

9.40

+0.12

+1.29%

盘后9.44

+0.04+0.42%

19:51 EDT

最高9.81	最低9.26	成交量255.57万
今开9.40	昨收9.28	日振幅5.93%
总市值5.47亿	流通市值4.28亿	总股本5,814万
成交额2,420万	换手率5.61%	流通股本4,554万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAPR","market":"US","secType":"STK","nameCN":"Capricor Therapeutics Inc","latestPrice":9.4,"timestamp":1788552000000,"preClose":9.28,"halted":0,"volume":2555651,"hourTrading":{"tag":"盘后","latestPrice":9.4397,"preClose":9.4,"latestTime":"19:51 EDT","volume":70079,"amount":658416.5087,"timestamp":1788565900822,"change":0.0397,"changeRate":0.004223,"amplitude":0.009574},"delay":0,"changeRate":0.012931034482758728,"floatShares":45535100,"shares":58138989,"eps":-2.465889,"marketStatus":"休市中","change":0.12,"latestTime":"09-04 16:00:00 EDT","open":9.4,"high":9.81,"low":9.26,"amount":24195574.729480002,"amplitude":0.059267,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.465889,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.28,"preHourTrading":{"tag":"盘前","latestPrice":9.4,"preClose":9.28,"latestTime":"09:29 EDT","volume":35485,"amount":328963.55056,"timestamp":1788528599999,"change":0.12,"changeRate":0.012931,"amplitude":0.032328},"postHourTrading":{"tag":"盘后","latestPrice":9.4397,"preClose":9.4,"latestTime":"19:51 EDT","volume":70079,"amount":658416.5087,"timestamp":1788565900822,"change":0.0397,"changeRate":0.004223,"amplitude":0.009574},"volumeRatio":0.5053852633330801,"impliedVol":1.3543,"impliedVolPercentile":0.5238},"requestUrl":"/m/hq/s/CAPR","defaultTab":"news","newsList":[{"id":"1158517206","title":"Kaos Capital拟在Capricor Therapeutics提名两位独立董事候选人，并推动董事会主导并购及战略替代委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1158517206","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158517206?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:48","pubTimestamp":1787312890,"startTime":"0","endTime":"0","summary":"Kaos Capital宣布，计划在Capricor Therapeutics提名两名独立董事候选人，同时推动成立一个由董事会主导的并购与战略替代方案委员会。此举标志着该投资机构对Capricor治理结构及战略方向提出了更为积极的介入姿态。Kaos Capital表示，此举旨在强化董事会的独立性与专业能力，从而为公司的长期价值创造提供更具前瞻性的决策基础。通过引入独立董事并设立专门委员会，Kaos Capital希望推动Capricor在战略决策层面实现更高透明度与效率。目前，Capricor方面尚未对上述提名及建议作出公开回应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102152981","title":"Capricor Therapeutics 将于8月13日公布2026年第二季度财务业绩并更新近期公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1102152981","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102152981?lang=zh_cn&edition=full","pubTime":"2026-08-10 20:31","pubTimestamp":1786365080,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics 宣布，计划于2026年8月13日发布第二季度财务报告。届时，公司还将同步提供近期业务进展的最新情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118640941","title":"FDA顾问委员会否决杜氏肌营养不良心脏病疗法，Capricor Therapeutics盘前重挫52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118640941","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118640941?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:13","pubTimestamp":1785409999,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics（股票代码：CAPR）的股价在盘前交易中暴跌52%，原因在于美国食品药品监督管理局（FDA）的一个顾问委员会投票反对该公司的杜氏肌营养不良心脏病治疗方案。这一关键性投票结果重挫了市场对这家生物技术公司的信心。投资者纷纷抛售股票，导致其盘前市值大幅蒸发，进一步凸显了监管审查在制药行业中的决定性影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102061346","title":"Piper Sandler下调Capricor Therapeutics评级：从增持降至中性，目标价从58美元猛砍至2美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102061346","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102061346?lang=zh_cn&edition=full","pubTime":"2026-07-30 13:30","pubTimestamp":1785389410,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics Inc遭受重挫。Piper Sandler今日宣布，将该公司股票评级由“增持”下调至“中性”。更令人震惊的是，其目标价被大幅削减——从原先的58美元骤降至仅2美元。这一调整幅度之大，引发市场广泛关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171813223","title":"FDA审查报告称疗效数据缺乏实质性证据，Capricor Therapeutics股价盘前暴跌60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171813223","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171813223?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:19","pubTimestamp":1785154749,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics（股票代码：CAPR）的股价在盘前交易中遭遇重挫，跌幅高达60%。这一暴跌的直接导火索，源于美国食品药品监督管理局（FDA）内部工作人员的审查报告。该报告明确指出，公司针对杜氏肌营养不良症（Duchenne）开发的细胞疗法，其所提交的数据并未能提供显著的疗效证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124723240","title":"Capricor Therapeutics宣布FDA咨询委员会将召开会议审查Deramiocel治疗杜氏肌营养不良症的生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1124723240","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124723240?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:16","pubTimestamp":1782483391,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics宣布，美国食品药品监督管理局（FDA）的咨询委员会将召开会议，以审查其候选药物Deramiocel用于治疗杜氏肌营养不良症（DMD）的生物制剂许可申请（BLA）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101669758","title":"Capricor Therapeutics：可用现金、现金等价物及有价证券足以支撑其运营至2027年第四季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1101669758","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101669758?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:18","pubTimestamp":1778617095,"startTime":"0","endTime":"0","summary":"生物技术公司Capricor Therapeutics Inc. 宣布，其当前持有的可用现金、现金等价物及市场流通有价证券，预计足以覆盖公司运营支出及资本需求，直至2027年第四季度。这一资金状况为公司推进其核心研发管线提供了坚实的财务保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137341631","title":"Capricor Therapeutics指控Ns Pharma未做好Deramiocel上市准备并违反协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1137341631","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137341631?lang=zh_cn&edition=full","pubTime":"2026-05-08 04:44","pubTimestamp":1778186647,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新披露的文件，生物制药公司Capricor Therapeutics已正式指控其合作伙伴Ns Pharma未能充分准备Deramiocel疗法的商业化上市工作，并涉嫌违反双方既定的合作协议。该文件显示，Capricor方面认为Ns Pharma在推进细胞疗法Deramiocel的上市筹备过程中存在重大疏漏，未能履行协议约定的商业推广责任。此次纠纷可能对Deramiocel这一备受关注的创新疗法的市场推进计划产生直接影响。业界正密切关注这一商业纠纷的后续发展，特别是其对Deramiocel疗法上市时间表的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179000631","title":"Capricor Therapeutics将于5月12日公布2026年第一季度财报并更新企业动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1179000631","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179000631?lang=zh_cn&edition=full","pubTime":"2026-05-05 04:06","pubTimestamp":1777925181,"startTime":"0","endTime":"0","summary":"生物制药公司Capricor Therapeutics Inc（股票代码：CAPR）宣布，将于2026年5月12日发布第一季度财务业绩报告。届时，公司管理层将同步披露最新业务进展与战略规划。\n此次财报发布将涵盖公司核心产品线的研发进度、商业化布局以及财务状况等关键信息。投资者可通过电话会议或网络直播参与业绩说明会，与管理层直接交流。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518279724","title":"Capricor Therapeutics, Inc.盘中异动 股价大跌5.15%报12.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518279724?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:00","pubTimestamp":1741615239,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时00分，Capricor Therapeutics, Inc.股票出现波动，股价急速下跌5.15%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3087.26%、661.78%、287.22%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220039abf3078e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220039abf3078e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516378816","title":"Capricor Therapeutics, Inc.盘中异动 早盘快速跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516378816","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516378816?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:52","pubTimestamp":1741013572,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时52分，Capricor Therapeutics, Inc.股票出现异动，股价急速下挫5.00%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为687.54%、115.08%、86.65%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、40.78%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032252529637b25c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032252529637b25c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514967857","title":"Capricor Therapeutics, Inc.盘中异动 快速下跌5.00%报15.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514967857","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514967857?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:52","pubTimestamp":1740585161,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时52分，Capricor Therapeutics, Inc.股票出现波动，股价大幅下挫5.00%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5442.90%、206.70%、195.43%，振幅较大的相关个股有Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Humacyte Inc C/Wts 27/08/2026 ，振幅分别为161.02%、43.31%、39.47%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262352419893ba47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262352419893ba47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778370","title":"Capricor Therapeutics, Inc.盘中异动 股价大跌5.20%报14.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513778370?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:56","pubTimestamp":1740409003,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时56分，Capricor Therapeutics, Inc.股票出现异动，股价大幅下跌5.20%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为142.31%、59.62%、25.08%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242256449890fc11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242256449890fc11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAPR","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512111193","title":"Capricor Therapeutics, Inc.盘中异动 下午盘股价大跌5.02%报15.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512111193","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512111193?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:17","pubTimestamp":1739902679,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时17分，Capricor Therapeutics, Inc.股票出现波动，股价快速下挫5.02%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.55%。其相关个股中，Aditxt, Inc.、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为667.76%、198.57%、164.56%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219021759988a21c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219021759988a21c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CAPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509323572","title":"Capricor Therapeutics, Inc.盘中异动 早盘快速跳水5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509323572","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509323572?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:16","pubTimestamp":1738772201,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日00时16分，Capricor Therapeutics, Inc.股票出现异动，股价快速下挫5.11%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.30%。其相关个股中，Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4256.80%、1754.28%、1304.65%，振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028，振幅分别为99.51%、59.80%、54.05%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020600164196191b62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020600164196191b62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAPR","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507717671","title":"Capricor Therapeutics, Inc.盘中异动 下午盘快速上涨5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507717671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507717671?lang=zh_cn&edition=full","pubTime":"2025-01-31 02:36","pubTimestamp":1738262178,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日02时36分，Capricor Therapeutics, Inc.股票出现波动，股价大幅上涨5.47%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Nutriband Inc C/Wts 涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1768.86%、288.24%、236.24%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 、Alterity Therapeutics Limited，振幅分别为65.98%、63.82%、61.86%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013102361996145887&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013102361996145887&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503284836","title":"Capricor Therapeutics, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503284836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503284836?lang=zh_cn&edition=full","pubTime":"2025-01-15 23:02","pubTimestamp":1736953340,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日23时02分，Capricor Therapeutics, Inc.股票出现波动，股价急速上涨5.00%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.16%。其相关个股中，Dermata Therapeutics Inc C/Wts 、Exicure, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Os Therapies Incorporated较为活跃，换手率分别为197.30%、121.96%、72.63%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Os Therapies Incorporated、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为68.03%、60.10%、54.40%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152302209867440d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152302209867440d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493579019","title":"Capricor Therapeutics盘中异动 快速上涨5.05%报13.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493579019","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493579019?lang=zh_cn&edition=full","pubTime":"2024-12-24 04:24","pubTimestamp":1734985493,"startTime":"0","endTime":"0","summary":"北京时间2024年12月24日01时21分，Capricor Therapeutics, Inc.股票出现波动，股价急速上涨5.05%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。Deramiocel 目前正处于治疗杜氏肌营养不良症的 3 期临床开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224042454ab8ed44a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224042454ab8ed44a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492612717","title":"Capricor Therapeutics, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492612717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492612717?lang=zh_cn&edition=full","pubTime":"2024-12-17 01:11","pubTimestamp":1734369082,"startTime":"0","endTime":"0","summary":"北京时间2024年12月17日01时11分，Capricor Therapeutics, Inc.股票出现异动，股价急速拉升5.02%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.83%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217011122984c73d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217011122984c73d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491051843","title":"Capricor Therapeutics, Inc.盘中异动 快速跳水5.09%报13.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491051843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2491051843?lang=zh_cn&edition=full","pubTime":"2024-12-14 01:34","pubTimestamp":1734111268,"startTime":"0","endTime":"0","summary":"北京时间2024年12月14日01时34分，Capricor Therapeutics, Inc.股票出现波动，股价大幅下跌5.09%。Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.67%。Capricor Therapeutics, Inc.公司简介：Capricor Therapeutics Inc 是一家生物技术公司，专注于推进转化细胞和外泌体疗法，以重新定义罕见疾病的治疗前景。Deramiocel 目前正处于治疗杜氏肌营养不良症的 3 期临床开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241214013429ab75dca1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241214013429ab75dca1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAPR","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.capricor.com","stockEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":1.3919},{"period":"3month","weight":-0.6481},{"period":"6month","weight":-0.6631},{"period":"1year","weight":0.5825},{"period":"ytd","weight":-0.6743}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Capricor Therapeutics, Inc.于2005年8月在特拉华州注册成立。该公司是一家专注于开发细胞和外泌体疗法的生物技术公司，主要用于治疗杜氏肌营养不良症。其主要候选药物Deramiocel是一种细胞疗法，目前正在接受FDA审查，用于治疗DMD的心脏和骨骼肌并发症。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.12654},{"month":2,"riseRate":0.545455,"avgChangeRate":0.012535},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.010585},{"month":4,"riseRate":0.5,"avgChangeRate":0.425005},{"month":5,"riseRate":0.25,"avgChangeRate":-0.148881},{"month":6,"riseRate":0.583333,"avgChangeRate":0.015874},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001516},{"month":8,"riseRate":0.583333,"avgChangeRate":0.138991},{"month":9,"riseRate":0.416667,"avgChangeRate":0.315531},{"month":10,"riseRate":0.090909,"avgChangeRate":-0.099314},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.0945},{"month":12,"riseRate":0.181818,"avgChangeRate":0.280594}],"exchange":"NASDAQ","name":"Capricor Therapeutics Inc","nameEN":"Capricor Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Capricor Therapeutics Inc(CAPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Capricor Therapeutics Inc(CAPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Capricor Therapeutics Inc,CAPR,Capricor Therapeutics Inc股票,Capricor Therapeutics Inc股票老虎,Capricor Therapeutics Inc股票老虎国际,Capricor Therapeutics Inc行情,Capricor Therapeutics Inc股票行情,Capricor Therapeutics Inc股价,Capricor Therapeutics Inc股市,Capricor Therapeutics Inc股票价格,Capricor Therapeutics Inc股票交易,Capricor Therapeutics Inc股票购买,Capricor Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Capricor Therapeutics Inc(CAPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Capricor Therapeutics Inc(CAPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}